Renal health is a critical aspect of patient wellbeing. Understanding the connection between common medications and potential kidney damage helps clinicians make informed decisions, enhancing patient outcomes.

SIVAD Diagnostic Medical Group’s novel drug testing strips, HarmGuard FX, are making strides in harm reduction, beginning in Delaware. These strips, a part of the wider Harm Stopper Program, signal a potential turning point in the battle against the national opioid crisis.

Gadoquatrane, a promising GBCA, enters Phase 3 clinical testing, potentially offering safer MRI procedures and advancing diagnostic capabilities for patients with CNS disorders, including MS.

As we grapple with the opioid crisis, this comprehensive study offers crucial insights into the intersection of state medical cannabis laws and chronic noncancer pain treatment, and posits no significant changes in pain treatment due to these laws.

The surprising association between CHIP and a lowered risk of Alzheimer’s disease offers a novel perspective in our understanding of neurodegenerative disorders and paves the way for potential future therapeutics.

Emerging research uncovers potential associations between the use of menopausal hormone therapy and an increased risk of dementia, including Alzheimer’s disease. Discover more about the implications of these findings for women’s health management.